The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
Open accessAbstract
Background: Despite advances in the first-line treatment of metastatic renal cell carcinoma (mRCC), effective options are needed to address disease progression during or following treatment with immune checkpoint inhibitors (ICIs). Thus, we aimed to evaluate lenvatinib plus pembrolizumab in these patients. Methods: We report results of the mRCC cohort from an open-label phase 1b/2 study of lenvatinib plus pembrolizumab in patients at least 18 years old with selected solid tumors and an ECOG PS of 0–1. Oral lenvatinib 20 mg was given daily along with intravenous pembrolizumab 200 mg once every three weeks. Efficacy was analyzed in patients with clear cell mRCC receiving study drug by prior therapy grouping: treatment-naïve, previously treated ICI-naïve, and ICI-pretreated patients. Safety was analyzed in all patients. The primary endpoint was objective response rate at week 24 (ORRwk24) per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) by investigator assessment. Tumor assessments occurred every six weeks until week 24, then every nine weeks. This trial is registered with ClinicalTrials.gov(NCT02501096); the final analysis is reported here. Findings: The study enrolled 145 patients (efficacy analysis, n=143; safety analysis, n=145) from July 21, 2015-October 16, 2019; median follow-up was 19·8 months (interquartile range: 14·3–28·4). The ORRwk24 by irRECIST was 72·7% (95% CI 49·8–89·3) for treatment-naïve patients (16/22), 41·2% (95% CI 18·4–67·1) for previously treated ICI-naïve patients (7/ 17), and 55·8% (95% CI 45·7–65·5) for ICI-pretreated patients (58/104). The most common grade 3 treatment-related adverse event (AE) was hypertension (treatment-naïve: 23%, 5/22; previously treated ICI-naïve: 18%, 3/17; ICI-pretreated: 21%, 22/104). Treatment-related serious AEs occurred in 36 patients; three had treatment-related deaths (gastrointestinal hemorrhage, sudden death, and pneumonia). Interpretation: Lenvatinib plus pembrolizumab showed encouraging antitumor activity and a manageable safety profile and may be an option for post-ICI treatment of mRCC. Funding: Eisai Inc.; Merck Sharp & Dohme Corp.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationPembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Self-citationiRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026982 · Cited by 1,791
Self-citation
Cited by
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Chang, Y.-H., Hajek, J., Symeonides, S. N., Lee, J. L., Sarwar, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106391 · Cited by 785
Self-citationKidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Alva, A., Baine, M., Beckermann, K., Carlo, M. I., Choueiri, T. K., Costello, B. A., Derweesh, I. H., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0001 · Cited by 667
Self-citationSignal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Metadata
- Authors
- Lee, C.-H., Shah, A. Y., Rasco, D., Rao, A., Taylor, M. H., Di Simone, C., Hsieh, J. J., Pinto, A., Shaffer, D. R., Girones Sarrio, R., Cohn, A. L., Vogelzang, N. J., Bilen, M. A., Gunnestad Ribe, S., Goksel, M., Tennøe, Ø. K., Richards, D., Sweis, R. F., Courtright, J., Heinrich, D., Jain, S., Wu, J., Schmidt, E. V., Perini, R. F., Kubiak, P., Okpara, C. E., Smith, A. D., & Motzer, R. J.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 22
- Issue
- 7
- Pages
- 946-958
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3167370803
- Cited by
- 187
- References
- 4
- FWCI
- 21.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00241-2
- The paper
- Lee, C.-H., Shah, A. Y., Rasco, D., Rao, A., Taylor, M. H., Di Simone, C., Hsieh, J. J., Pinto, A., Shaffer, D. R., Girones Sarrio, R., Cohn, A. L., Vogelzang, N. J., Bilen, M. A., Gunnestad Ribe, S., Goksel, M., Tennøe, Ø. K., Richards, D., Sweis, R. F., Courtright, J., . . . Motzer, R. J. (2021). Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00241-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.